DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2004/0005359 A1 Cheng Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2004/0005359 A1 Cheng Et Al US 2004.0005359A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0005359 A1 Cheng et al. (43) Pub. Date: Jan. 8, 2004 (54) CONTROLLED RELEASE ORAL DOSAGE (22) Filed: Jun. 27, 2002 FORM Publication Classification (76) Inventors: Xiu Xiu Cheng, Davie, FL (US); Chih Ming Chen, Davie, FL (US); Dacheng (51) Int. Cl.' ..................... A61K 31/554; A61K 31/277; Tian, Miramar, FL (US) A61K 31/455; A61K 9/24 (52) U.S. Cl. .................... 424/471; 514/211.07: 514/355; Correspondence Address: 514/523 Martin P. Endres, Esq. HEDMAN & COSTIGAN, PC. (57) ABSTRACT 1185 Avenue of the Americas A Sustained-release pharmaceutical preparation is disclosed New York, NY 10036 (US) in which a calcium channel blocker, preferably Verapamil, core is Surrounded by an optional Seal coat layer and a (21) Appl. No.: 10/183,776 water-insoluble coating. 8 O S.3S O C 2 6 O O f 92 O o O E CC 1O Dissolution Time (Hour) -e- SF -a - SGF Patent Application Publication Jan. 8, 2004 Sheet 1 of 5 US 2004/0005359 A1 st N 1-N h OS O O w N1 O) E co C .9 --d 2 C d V2 O O O O CO CO r (%) panoSSIO unouw Patent Application Publication Jan. 8, 2004 Sheet 2 of 5 US 2004/0005359 A1 8|910Z -OZ}ºddy:-IL@Zºtud- -±- 08 09$ 0?7± Š „~, C) 9. % S? 8 Patent Application Publication Jan. 8, 2004 Sheet 3 of 5 US 2004/0005359 A1 S : 1N No1T D - S.Sst O pm g OO O ca .2 VO A o d C CO Vo rt (%) peAIOSSCI Junou IV Patent Application Publication Jan. 8, 2004 Sheet 4 of 5 US 2004/0005359 A1 Mean Verapamil Concentration of Example 1 vs. Time Fasting 150 E 1 OO dh S. 2 3 16, 20 Time (hours) FG. 4 Patent Application Publication Jan. 8, 2004 Sheet 5 of 5 US 2004/0005359 A1 Mean Verapamil Concentration of Example 1 vs. Time Fed e 1 OO d S US 3 50 2O 24 28 Time (hours) -a- Covera HS (8J127) F.G. 5 US 2004/0005359 A1 Jan. 8, 2004 CONTROLLED RELEASE ORAL DOSAGE FORM layer and a push layer containing pharmacologically inert (but osmotically active) components. However, the manu BACKGROUND OF THE INVENTION facturing of this multi-layer core System proves to be difficult and expensive. This system, disclosed in U.S. Pat. 0001) 1. Field of the Invention No. 5,252.338 is incorporated herein by reference. Varia 0002 The present invention relates to oral controlled tions on the osmotic System are also disclosed in U.S. Pat. release dosage formulations containing a calcium channel No. 4,783,337 and 4,753,802 which are incorporated herein blocking agent. More specifically, the present invention by reference. relates to an oral dosage formulation in the form of a coated 0008 Another Sustained release formulation disclosed in Single composition core tablet comprising a calcium channel U.S. Pat. No. 4,863,742 (incorporated herein by reference) blocking agent, Such as amlodipine, diltiazem, nicardipine, requires a core comprised of layers of polymeric material nifedipine, Verapamil, felodipine, isradipine, nisoldipine, Superimposed on layers of Verapamil. The core is Sur nimodipine, nilvadipine, flunarizine, norVerapamil, nitre rounded by a multi-layer membrane with a major portion of dipine, cinnarizine, fendiline or their pharmaceutically a water Soluble polymer and a minor portion of a water acceptable derivatives, Salts and Stereoisomers. Preferably, insoluble polymer. The formulation contains a first compo the calcium channel blocking agent is Verapamil. nent that provides an effective amount of Verapamil within 0003 2. Description of the Prior Art one hour after administration and a Second component that 0004 Verapamil (+/-)-5-[(3,4-Dimethoxyphenethyl)m- provides an effective amount of Verapamil 6-16 hours after ethylamino-2-(3,4-dimethoxyphenyl)-2-isopropylvaleroni administration. trile monohydrochloride or iproveratril is a nondihydropy 0009. One limitation associated with these prior art dos ridine calcium channel blocking agent that inhibits the age forms is that many of the multi-walled preparations transmembrane influx of extracellular calcium ions acroSS described above do not provide a therapeutic release of the the membranes of the myocardial cells and vascular Smooth drug prior to initiation of Sustained release, which is impor muscle cells, without changing Serum calcium concentra tant when biphasic release profiles are desired. tions. By inhibiting calcium influx, Verapamil inhibits the 0010. Other systems are essentially “delayed' release contractile processes of cardiac and vascular Smooth muscle, thereby dilating the main coronary and Systemic arteries. mechanisms wherein there is a delay of drug release in the Verapamil is a class IV antiarrhythmic. It reduces afterload Stomach but once the coated drug reaches the intestines, the and myocardial contractility. release of medication is rapid. 0.011 Verapamil is also available as controlled and 0005 Verapamil is used orally to treat Prinzmetal variant extended release capsules (Verelan SRE) containing pellets angina and unstable and chronic Stable angina pectoris, the and as extended release caplets (Calan SRCR), Isoptin SR(R). management of hypertension, for the prevention of recurrent The extended release capsules contain controlled release premature Supraventricular tachycardia (PSVT) and, in com beads, a portion of which are uncoated for immediate bination with a cardiac glycoside, to control ventricular rate release. The remainder consists of a drug core with rate at rest and during StreSS in patients with atrial flutter and/or controlling polymeric coating. The extended release caplets fibrillation. It has been used as adjunctive therapy in the contain alginate which SWells in water and forms a gelati management of hypertrophic cardiomyopathy or in certain nous like substance. Verapamil is released both by diffusion patients after myocardial infarction when beta-adrenergic out of the gel and by erosion of the tablet. Verapamil shows blocking agents are ineffective or contraindicated for the linear pharmacokinetics for Single dosing, but Saturation and relief of ongoing ischemia. Benefit has also been demon increased bioavailability with multiple dosing. Because of Strated in the management of manic manifestations of bipo their pharmacokinetic profile, these are dosed early in the lar disorder. morning, rather than at bedtime. For many patients, these are 0006 Numerous techniques are in the prior art for pre dosed every twelve hours in the morning and in the evening. paring Sustained or controlled release pharmaceutical for Additionally, the caplets should be administered with food to mulations. One common technique involves Surrounding an prevent wide differences between peak and trough Serum oSmotically active drug core with a Semipermeable mem Verapamil concentrations. brane or wall. The drug is released from the core by allowing 0012. The need exists for a sustained release pharmaceu a fluid Such as gastric or intestinal fluid to permeate the tical preparation which provides constant blood levels, and coating membrane and dissolve the drug So dissolved drug is Simply and economically produced. Such a delivery can permeate the membrane. In Some cases a hydrogel is dosage form has a practical application, and it represents a employed to push the active ingredient through the passage valuable contribution to the medical arts. The present inven way in the membrane. The hydrogel imbibes fluid and tion provides Such a composition, and offers an efficient and expands thereby pushing the active ingredient through the cost effective method of preparation. membrane or passageway formed in the membrane and from the dosage form. 0013. Accordingly, it is an object of this invention to provide a novel and useful dosage form for administering a 0007. Several different Sustained release formulations of calcium channel blocking agents are patented. Commer calcium channel blocker, preferably Verapamil, that repre cially available extended-release tablets of Verapamil hydro Sents an unexpected improvement in the art and Substantially chloride (Covera-HS(R) contain drug in an osmotic delivery overcomes the disadvantages known to the prior art. System consisting of an OSmotically active core Surrounded 0014. It is an object of this invention to provide a by a semipermeable membrane with a laser-drilled delivery Sustained release form of a calcium channel blocker, pref orifice. The core itself is divided into 2 layers: an active drug erably Verapamil, Suitable for bedtime administration, which US 2004/0005359 A1 Jan. 8, 2004 is Substantially invariable from Subject to Subject, and pro antihypertensive effect remaining at the end of the dosing vides Significant plasma levels of the calcium channel interval. Release of the calcium channel blocker does not blocker which are maintained for an extended period after occur until about two hours after administration. The prod administration. uct peaks and maintains levels from 10-24 hours. The usual 0.015. Another object of the invention is to provide bed dosage range is 80 mg-480 mg. time dosing of Verapamil resulting in therapeutic morning levels to reduce the early morning rise in blood pressure and BRIEF DESCRIPTION OF THE DRAWINGS heart rate. 0022 FIG. 1 is a graph depicting the dissolution profile in Simulated intestinal fluid (pH 6.8) and Simulated gastric 0016. Another object of this invention is to provide 24 fluid (pH 1.2) of the formulation as described in Example 1 hour control of hypertension and angina. as tested according to the procedure described in United 0.017. Other objects, features and advantages of the States Pharmacopoeia (USP) XXIII, Apparatus 2 (a 75 rpm. invention are not taught in the prior art but will be more 0023 FIG. 2 is a graph depicting the dissolution profile apparent to those versed in the art from the following in a pH 7.5 buffer of the formulation in Example 2 as tested Specification, taken in conjunction with the drawings and the according to the procedure described in USP XXIII, Appa accompanying claims.
Load more

Recommended publications
  • Gabab Regulation of Methamphetamine-Induced Associative Learning
    Loyola University Chicago Loyola eCommons Dissertations Theses and Dissertations 2010 Gabab Regulation of Methamphetamine-Induced Associative Learning Robin Michelle Voigt Loyola University Chicago Follow this and additional works at: https://ecommons.luc.edu/luc_diss Part of the Pharmacology Commons Recommended Citation Voigt, Robin Michelle, "Gabab Regulation of Methamphetamine-Induced Associative Learning" (2010). Dissertations. 38. https://ecommons.luc.edu/luc_diss/38 This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more information, please contact [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. Copyright © 2010 Robin Michelle Voigt LOYOLA UNIVERSITY CHICAGO GABAB REGULATION OF METHAMPHETAMINE-INDUCED ASSOCIATIVE LEARNING A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL IN CANDIDACY FOR THE DEGREE OF DOCTOR OF PHILOSOPHY PROGRAM IN MOLECULAR PHARMACOLOGY & THERAPEUTICS BY ROBIN MICHELLE VOIGT CHICAGO, IL DECEMBER 2010 Copyright by Robin Michelle Voigt, 2010 All rights reserved ACKNOWLEDGEMENTS Without the support of so many generous and wonderful individuals I would not have been able to be where I am today. First, I would like to thank my Mother for her belief that I could accomplish anything that I set my mind to. I would also like to thank my dissertation advisor, Dr. Celeste Napier, for encouraging and challenging me to be better than I thought possible. I extend gratitude to my committee members, Drs. Julie Kauer, Adriano Marchese, Micky Marinelli, and Karie Scrogin for their guidance and insightful input.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Download Product Insert (PDF)
    Product Information Fendiline (hydrochloride) Item No. 17295 CAS Registry No.: 13636-18-5 Formal Name: γ-phenyl-N-(1-phenylethyl)- benzenepropanamine, monohydrochloride MF: C23H25N • HCl FW: 351.9 N Purity: ≥95% H Stability: ≥2 years at -20°C Supplied as: A crystalline solid • HCl Laboratory Procedures For long term storage, we suggest that fendiline (hydrochloride) be stored as supplied at -20°C. It should be stable for at least two years. Fendiline (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the fendiline (hydrochloride) in the solvent of choice. Fendiline (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of fendiline (hydrochloride) in these solvents is approximately 15, 30, and 20 mg/ml, respectively. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of fendiline (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of fendiline (hydrochloride) in PBS, pH 7.2, is approximately 0.1 mg/ml. We do not recommend storing the aqueous solution for more than one day. α Fendiline is an 2-adrenergic receptor antagonist (Kd = 2.6 µM) and an L-type calcium channel blocker (IC50 = 17 µM) well-known for its coronary vasodilator effects.1-4 Fendiline has recently been reported to inhibit K-Ras plasma membrane localization (IC50 = 9.64 µM), which prevents K-Ras signal transduction and blocks the proliferation of K-Ras-transformed tumor cells.5 References 1.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • WO 2013/061161 A2 2 May 2013 (02.05.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/061161 A2 2 May 2013 (02.05.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/337 (2006.01) A61K 31/48 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/395 (2006.01) A61K 31/51 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/4174 (2006.01) A61K 31/549 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/428 (2006.01) A61K 31/663 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (21) International Application Number: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, PCT/IB20 12/002768 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (22) International Filing Date: NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, 25 October 2012 (25.10.2012) RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (25) Filing Language: English ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/552,922 28 October 201 1 (28.
    [Show full text]
  • A Complete Toxicology Screening Procedure for Drugs and Toxic Compounds in Urine and Plasma Using LC-MS/MS
    Application Note: 449 A Complete Toxicology Screening Procedure for Drugs and Toxic Compounds in Urine and Plasma Using LC-MS/MS Marta Kozak, Taha Rezai, Thermo Fisher Scientific, San Jose, CA Introduction Key Words Toxicology laboratories commonly use automated Scan Event 1 Scan Event 7 + Full Scan MS – Full Scan MS • ToxSpec immunoassays, gas chromatography-mass spectrometry Analyzer (GC-MS) and high pressure liquid chromatography-diode array detector (HPLC-DAD) techniques to perform • ToxID Software toxicology screening analyses. None of these techniques • LXQ Linear Ion are able to identify all the drugs and toxic compounds Trap that are potentially present in a sample. Implementation of liquid chromatography-mass spectrometry (LC-MS) for • Clinical toxicology screening provides specific and sensitive Toxicology analysis of drugs and toxic substances. The benefits of the • General LC-MS/MS screening methodology include a simple Unknown sample preparation procedure, ease of adding new Screening compounds to the screening method and fewer limitations based on compound volatility and thermal stability. In Scan Event 2-6 Scan Event 8-9 addition, Thermo Scientific ToxID automated toxicology + MS/MS on parent list – MS/MS on parent list screening software is able to automatically generate both Summary and Long Reports, avoiding the need for Figure 1: MS scan events manual analysis of each sample chromatogram. This application note describes the use of the Thermo Scientific LXQ ion trap mass spectrometer equipped with an ESI source and HPLC for identification of unknown compounds in human urine and human plasma. Step 1: Extract analytes from urine or plasma with SPE procedure Goal To develop a complete LC-MS/MS screening methodology which includes a sample preparation method, LC-MS Step 2: Analyze the samples method, spectra library, and data processing and reporting with LC-MS/MS method software.
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Dihydropyridine Receptor in Rat Brain Labeled With
    Proc. Nati. Acad. Sci. USA Vol. 80, pp. 2356-2360, April 1983 Medical Sciences Dihydropyridine receptor in rat brain labeled with [3H]nimodipine* (calcium antagonists/binding site/structural specificity/stereoselectivity/cerebrovascular diseases) P. BELLEMANN, A. SCHADE, AND R. TOWARTt Department of Pharmacology, Bayer AG, P.O. Box 10 17 09, D-5600 Wuppertal, Federal Republic of Germany Communicated by Helmut Beinert, December 20, 1982 ABSTRACT Receptor binding sites for 1,4-dihydropyridine potent analogue of nifedipine with cerebrovascular and neuro- (DHP) calcium antagonists have been characterized by using [3H]- and psychopharmacological actions (15, 16). nimodipine, a potent analogue of nifedipine with cerebrovascular and neuro- and psychopharmacological properties. [3H]Nimodi- MATERIALS AND METHODS pine exhibited reversible and saturable binding to partially pu- rified brain membranes. The equilibrium dissociation constant, Materials. [3H]Nimodipine (New England Nuclear) had a Kd, was 1.11 nM and the maximal binding capacity, Bma, was 0.50 specific activity of 160-180 Ci/mmol (1 Ci = 3.7 X 101 Bq) pmol/mg of protein. The DHP receptor proved to be highly spe- and its purity was continuously monitored by thin-layer radio- cific for various potently displacing DHP derivatives and discrim- chromatography. The ligand was stored light-protected (-300C) inated between their optical isomers (stereoselectivity) with in- under nitrogen gas to prevent radiolysis and oxidation. hibition constants (Ki) in the nanomolar or even subnanomolar The DHP derivatives nifedipine, nimodipine, niludipine, range. Structurally different calcium antagonists such as gallo- nisoldipine, nitrendipine, and BAY E 6927, the stereoisomers pamil (D-600), on the other hand, displayed much lower affinities, (Bayer AG, Wuppertal, Federal Republic of Germany), and further substantiating the specificity of the receptor for DHP calcium entry blockers or vasodilators without DHP structure structures.
    [Show full text]
  • Anatomical Classification Guidelines V2021 EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021 Anatomical Classification Guidelines V2021 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2021 Anatomical Classification Guidelines V2021 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 36 D DERMATOLOGICALS 51 G GENITO-URINARY SYSTEM AND SEX HORMONES 58 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 68 J GENERAL ANTI-INFECTIVES SYSTEMIC 72 K HOSPITAL SOLUTIONS 88 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 96 M MUSCULO-SKELETAL SYSTEM 106 N NERVOUS SYSTEM 111 P PARASITOLOGY 122 R RESPIRATORY SYSTEM 124 S SENSORY ORGANS 136 T DIAGNOSTIC AGENTS 143 V VARIOUS 145 Anatomical Classification Guidelines V2021 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Local Anesthetic Properties of Prenylamine Mustafa G
    Anesthesiology 2001; 95:1198–1204 © 2001 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Local Anesthetic Properties of Prenylamine Mustafa G. Mujtaba, Ph.D.,* Peter Gerner, M.D.,† Ging Kuo Wang, Ph.D.‡ Background: Local anesthetics that produce analgesia of long of the L-type calcium channels.3 Both ␣-subunits form a duration with minimal impairment of autonomic functions are fourfold pseudosymmetry with four repeated domains, highly desirable for pain management in the clinic. Pre- each with six transmembrane segments.3 There are nylamine is a known calcium channel blocker, but its local anesthetic blocking effects on voltage-gated sodium channels drugs that can block both calcium channels and 4,5 have not been studied thus far. NaChs. It has been reported that there is a correlation Methods: The authors characterized the tonic and use-depen- between the potencies of calcium channel blockers in ؉ dent prenylamine block of native Na channels in cultured rat preventing neurotoxicity induced by veratridine in brain neuronal GH cells during whole cell voltage clamp conditions Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/95/5/1198/334086/0000542-200111000-00025.pdf by guest on 02 October 2021 3 neuronal cultures and their binding affinity for and the local anesthetic effect of prenylamine by neurologic 3 6 evaluation of sensory and motor functions of sciatic nerve dur- [H ]batrachotoxinin-B binding sites. This raises a possi- ing neural block in rats. bility that some calcium channel blockers may block .Results: Prenylamine elicits both use-dependent block of Na؉ Naϩ channels with a high affinity channels during repetitive pulses (3 ␮M prenylamine produced Few LAs for pain management produce analgesia of 50% block at 5 Hz) and tonic block for both resting and inacti- ؉ long duration.
    [Show full text]
  • Identification of New Functional Inhibitors of Acid Sphingomyelinase
    J. Med. Chem. 2008, 51, 219–237 219 Identification of New Functional Inhibitors of Acid Sphingomyelinase Using a Structure-Property-Activity Relation Model Johannes Kornhuber,*,† Philipp Tripal,† Martin Reichel,† Lothar Terfloth,‡ Stefan Bleich,† Jens Wiltfang,† and Erich Gulbins£ Department of Psychiatry and Psychotherapy, UniVersity of Erlangen, Germany, Molecular Networks, Erlangen, Germany, and Department of Molecular Biology, UniVersity of DuisburgsEssen, Germany ReceiVed May 4, 2007 Some organic weak bases induce a detachment from inner lysosomal membranes and subsequent inactivation of acid sphingomyelinase (ASM) and thus work as functional ASM inhibitors. The aim of the present investigation was to develop a structure-property-activity relation (SPAR) model in order to specify the structural and physicochemical characteristics of probes capable of functionally inhibiting ASM. High pKa and high log P values are necessary but not sufficient preconditions for functional inhibition of ASM. The experimental data supported the requirement of an additional factor, which is necessary for functional inhibition of ASM. This factor k is related to the steric hindrance of the most basic nitrogen atom and presumably modulates the free presentation of a protonated nitrogen atom at the inner lysosomal surface. During the course of the study, we characterized 26 new functional ASM inhibitors, including doxepine 63, fluoxetine 104, maprotiline 109, nortriptyline 114, paroxetine 118, sertraline 124, suloctidil 125, and terfenadine 127. Introduction inactivation. Weak bases such as desipramine (17) result in a detachment of the ASM from the inner membrane21 and Eukaryotic cells have the ability to internally segregate subsequent inactivation, possibly by proteolytic degradation.22 aqueous compartments differing in pH using lipid bilayer Weak bases, therefore, do not directly inhibit ASM but result membranes and ATP-driven proton pumps.1–5 The lysosomal in a functional inhibition of ASM.
    [Show full text]